[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].
OBJECTIVE
To assess antituberculous efficacy, patients' compliance and application perspective of fixed-dose compounds rifater/rifinah in China.


METHODS
Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation.


RESULTS
The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively.


CONCLUSIONS
Fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China.
Zhu
L
L
Beijing Institute of Tuberculosis and Thoracic Tumor, Beijing 101149.
Yan
B
B
Ma
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000008:administration & dosage*; D012293:Rifampin / Q000008:administration & dosage*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin